Indian companies must make their own intermediates and support small industries: Dr. K. Nagaiah, Chief Scientist, CSIR - IICT, Hyderabad
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
_256_384.png)
Over 700 exhibitors from APAC, Europe, the US, and beyond showcased the latest in personal care innovation
This predictive technology empowers people with diabetes to take preventive action before complications arise
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
Speakers for the session are: Dr. Richard Lobo, Global Head Business Excellence, Innovation, R&D and Chief Ethics Counsellor, Tata Chemicals; Dr. Debabrata Rautaray, Vice President and Chief Product Development & Innovation Officer, DCM Shriram Chemicals Innovation Centre; Dr. Prashant Puri, Head - R&D, Deepak Fertilizers and Petrochemicals Corporation (DFPCL); Dr. Deepak S Panmand, General Manager (R&D), Dhanuka Agritech; Dr. Mudassir. K. Munshi, Team Leader, Deepak Nitrite; and Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals
Subscribe To Our Newsletter & Stay Updated
